In t(8;21)(q22;q22) acute myeloid leukemia, the prognostic value of early minimal residual disease assessed with real-time quantitative polymerase chain reaction is the most important prognostic factor, but how long-term minimal residual disease monitoring may contribute to drive individual patient decisions remains poorly investigated. In the multicenter CBF-2006 study, a prospective monitorin...

The significance of the polymerase chain reaction (PCR) in the detection of minimal residual disease in Philadelphia chromosome (Ph')-positive chronic myelogenous leukemia (CML) following interferon therapy was investigated. Forty remission blood samples obtained at various remission time points from 29 patients in complete cytogenetic remission were analyzed. All 40 samples showed minimal resi...

Incubation of chronic myeloid leukemia (CML) marrow for 10 days in vitro causes a marked and selective loss of very primitive Philadelphia chromosome (Ph)+ as compared with Ph- progenitors. We have autografted 22 patients with CML (16 in first chronic phase [group 1] and 6 with more advanced disease [group 2]) with marrow treated in this way to facilitate restoration of Ph- hematopoiesis after ...

OBJECTIVE Prediction of pathologic complete remission in breast cancer after preoperative therapy presents difficulties. We performed a meta-analysis to determine the ability of MRI to predict pathologic complete remission in patients with breast cancer after preoperative therapy. MATERIALS AND METHODS Medical subject heading terms ("MRI" and "Breast Neoplasm") and key words ("neoadjuvant" or...

Dogs with spontaneous lymphoma were treated with one of three aggressive treatment protocols: (1) combination chemotherapy with cyclophosphamide, L-asparaginase. Oncovin#{174}, and prednisone (CLOP); (2) combination chemotherapy with nitrogen mustard, Oncovin#{174}, prednisone, 1-asparaginase, and 6-mercaptopurine (MOPA-6); or (3) MOPA-6 followed by total-body irradiation (TBI) and autologous m...

Dogs with spontaneous lymphoma were treated with one of three aggressive treatment protocols: (1) combination chemotherapy with cyclophosphamide, L-asparaginase. Oncovin#{174}, and prednisone (CLOP); (2) combination chemotherapy with nitrogen mustard, Oncovin#{174}, prednisone, 1-asparaginase, and 6-mercaptopurine (MOPA-6); or (3) MOPA-6 followed by total-body irradiation (TBI) and autologous m...